Formulation of "Aftimoon habb and homul" Based on Iranian Traditional Pharmacy, Development of Standardization Method and Evaluation of the effect of homul on improving pelvic pain, quality of life and ovarian cyst size in endometriosis patients.

Evaluation of the Effects of Traditional Dosage form Called Hamol-e-Aftimone in Improving Pelvic Pain, Quality Of Life And Ovarian Cyst Size in Endometriosis Patients; A Double-Blind, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130911014630N11

Enrollment

Registered

2023-08-30

Start date

2024-02-20

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis

Interventions

Intervention 1: Intervention group: Receiving Homul(Suppository) of Aftimoon. Intervention 2: Control group: Receiving Placebo.

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age between 20 to 45 Endometriosis patients with pelvic pain and ovarian cyst over two centimeters Absence of Müllerian anomaly, fibrosis, adenomyosis and myoma No medication except NSAIDs for endometriosis within 6 months before referral Presence of patient's consent to participate in the study

Exclusion criteria

Exclusion criteria: pregnancy and lactation Sever and treatment resistant pain which candidates patient for surgary Absence of any acute and serious liver or kidney disease Absence of pap smear with intraepithelial pathological changes No history of any former or being treated malignancy

Design outcomes

Primary

Measure	Time frame
Amount of pain. Timepoint: At the beginning of the study, then during the study on period days 3 times a day. Method of measurement: Visual Analog scale.	—

Secondary

Measure	Time frame
Size of ovarian cyst. Timepoint: At the beginning of the study, after the first month and after the second month. Method of measurement: Trans-vaginal ultrasound.;Patient quality of life. Timepoint: At the beginning of the study, after the first month and after the second month. Method of measurement: Quality of life Questionnaire EHP30.;Painkiller consumption. Timepoint: At the beginning of the study, after the first month and after the second month. Method of measurement: Questionnaire.	—

Measure

Time frame

Size of ovarian cyst. Timepoint: At the beginning of the study, after the first month and after the second month. Method of measurement: Trans-vaginal ultrasound.;Patient quality of life. Timepoint: At the beginning of the study, after the first month and after the second month. Method of measurement: Quality of life Questionnaire EHP30.;Painkiller consumption. Timepoint: At the beginning of the study, after the first month and after the second month. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Alizade

Mazandaran University of Medical Sciences

ft.shamalizade@gmail.com+98 11 3228 0252

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026